Johnson & Johnson Expands Cardiac Ablation Options in Europe with Dual Energy Platform
Event summary
- Johnson & Johnson launched the Dual Energy THERMOCOOL SMARTTOUCH SF (DE STSF) Platform in Europe on June 25, 2026.
- The platform combines radiofrequency (RF) and pulsed field (PF) energy delivery through a single catheter-based solution.
- Clinical data from the SmartfIRE study showed 86.9% effectiveness among patients treated with high adherence to recommended workflows.
- The DE STSF Platform integrates with CARTO mapping, ultra-high-density mapping solutions, and intracardiac ultrasound imaging.
The big picture
Johnson & Johnson's launch of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform underscores the growing trend toward personalized and versatile treatment options in cardiac ablation. The platform's ability to deliver both RF and PF energy through a single catheter addresses the increasing complexity of atrial fibrillation procedures, positioning J&J as a leader in electrophysiology innovation. This expansion into Europe follows broader industry shifts toward integrated solutions that enhance procedural control and reproducibility.
What we're watching
- Adoption Pace
- How quickly European electrophysiologists will integrate the dual-energy platform into their existing workflows.
- Clinical Validation
- Whether long-term data will confirm the initial effectiveness and safety findings from the SmartfIRE study.
- Market Differentiation
- The extent to which Johnson & Johnson can leverage this technology to maintain its leadership position in cardiac ablation.